Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lexicon Pharmaceuticals, Inc. - Common Stock (NQ:LXRX)

2.375 +0.055 (+2.37%)
Streaming Delayed Price Updated: 3:56 PM EDT, Jul 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,116,182
Open 2.320
Bid (Size) 2.370 (11,500)
Ask (Size) 2.380 (30,500)
Prev. Close 2.320
Today's Range 2.260 - 2.435
52wk Range 0.8363 - 2.680
Shares Outstanding 144,474,452
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026? ↗
One company posts rapid revenue growth but remains unprofitable, while the other boasts global scale and steady cash flow. See how their fundamentals stack up. 
Via The Motley Fool
News headline image
Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions
Presentations highlight consistent A1c reductions with sotagliflozin in type 1 diabetes and pharmacokinetics of pilavapadin across renal function groups 
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire

Performance

YTD
+108.3%
+108.3%
1 Month
+26.3%
+26.3%
3 Month
+49.4%
+49.4%
6 Month
+108.3%
+108.3%
1 Year
+172.1%
+172.1%

More News

Read More
News headline image
Lexicon (LXRX) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
Lexicon Pharmaceuticals (NASDAQ:LXRX) Q1 2026 Results Show Revenue Beat and Narrowed Loss ↗
Via Chartmill
Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) Beats Q4 Estimates and Strengthens Cash Runway ↗
Via Chartmill
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) Shows High-Growth Momentum with Strong Technical and Fundamental Trends ↗
Via Chartmill
News headline image
Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Pharmaceuticals Q1 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies & Treatments for Diabetes
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon (LXRX) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Pharmaceuticals to Participate in Three Upcoming March Investor Conferences
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Results on March 5, 2026
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Announces Proposed Public Offering of Common Stock
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Lexicon Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Lexicon Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Lexicon Pharmaceuticals, Inc. - Common Stock trade on?
Lexicon Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Lexicon Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Lexicon Pharmaceuticals, Inc. - Common Stock is LXRX on the Nasdaq Stock Market
What is the current price of Lexicon Pharmaceuticals, Inc. - Common Stock?
The current price of Lexicon Pharmaceuticals, Inc. - Common Stock is 2.375
When was Lexicon Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Lexicon Pharmaceuticals, Inc. - Common Stock was at 07/07/26 03:56 PM ET
What is the market capitalization of Lexicon Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Lexicon Pharmaceuticals, Inc. - Common Stock is 343.13M
How many shares of Lexicon Pharmaceuticals, Inc. - Common Stock are outstanding?
Lexicon Pharmaceuticals, Inc. - Common Stock has 343M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.